期刊文献+

血清铁蛋白及LDH检测对侵袭性淋巴瘤预后意义

PROGNOSTIC SIGNIFICANCE OF SERUM FERRITIN AND LACTATE DEHYDROGENASE IN PATIENTS WITH AGGRESSIVE LYMPHOMA
下载PDF
导出
摘要 目的 探讨血清铁蛋白(FERR)及乳酸脱氢酶(LDH)检测对初治侵袭性淋巴瘤病人预后意义。方法回顾性分析于我院就诊的182例初治侵袭性淋巴瘤病人的临床资料。根据受试者工作特征(ROC)曲线计算约登指数得出血清FERR、LDH截断值,据此将病人分为高FERR高LDH组(47例)、低FERR低LDH组(67例)和其他组(68例,包括低FERR高LDH组42例和高FERR低LDH组26例),分析血清FERR、LDH水平对初治侵袭性淋巴瘤病人预后的影响。结果 中位随访时间22个月,血清FERR、LDH联合检测的曲线下面积(AUC)高于两者单独检测的AUC。高FERR高LDH组病人的总生存时间(OS)和无进展生存时间(PFS)均短于另外两组,差异具有统计学意义(χ^(2)=30.568、40.759,P<0.001)。多因素分析显示,血清FERR是影响初治侵袭性淋巴瘤病人OS、PFS的独立危险因素。结论 血清FERR、LDH联合检测是判断初治侵袭性淋巴瘤病人预后的有用指标,二者水平均升高提示病人预后较差。 Objective To investigate the prognostic significance of combined detection of serum ferritin(FERR) and lactate dehydrogenase(LDH) in previously untreated patients with aggressive lymphoma. Methods The clinical data of 182 pre-viously untreated patients with aggressive lymphoma who were admitted to our hospital were analyzed retrospectively. The cut-off values of serum FERR and LDH were determined by calculating the Youden’s index based on the receiver operating characteristic(ROC) curve. According to the cut-off values, patients were divided into high FERR and high LDH group(n=47), low FERR and low LDH group(n=67), and other group(n=68, including 42 patients with low FERR and high LDH and 26 patients with high FERR and low LDH). The influence of serum FERR and LDH on the prognosis of previously untreated patients with aggressive lymphoma was analyzed. Results The median follow-up time was 22 months. The area under the ROC curve of the combined measurement of serum FERR and LDH was higher than that of serum FERR or LDH alone. Patients in the high FERR and high LDH group had significantly shorter overall survival(OS) and progression-free survival(PFS) than those in the other two groups(χ^(2)=30.568,40.759;P<0.001). Multivariate analysis showed that serum FERR was an independent risk factor for OS and PFS in previously untreated patients with aggressive lymphoma. Conclusion The combined measurement of serum FERR and LDH is a useful indicator for evaluating the prognosis of previously untreated patients with aggressive lymphoma. Elevated levels of both se-rum FERR and LDH indicate a poor prognosis in patients.
作者 宋峤 曹正 武智敏 吴少玲 赵新东 顾华丽 SONG Qiao;CAO Zheng;WU Zhimin;WU Shaoling;ZHAO Xindong;GU Huali(Department of Hematology,The Affiliated Hospital of Qingdao University,Qingdao 266555,China)
出处 《青岛大学学报(医学版)》 CAS 2022年第6期844-850,共7页 Journal of Qingdao University(Medical Sciences)
基金 山东省自然科学基金项目(ZR2019MH096)。
关键词 淋巴瘤 肿瘤浸润 铁蛋白质类 L-乳酸脱氢酶 预后 lymphoma neoplasm invasiveness ferritins L-lactate dehydrogenase prognosis
  • 相关文献

参考文献3

二级参考文献62

  • 1石远凯,刘鹏,杨晟,韩晓红,何小慧,艾斌,秦燕,李博,黄鼎智,张长弓,孙燕.注射用聚乙二醇化重组人粒细胞集落刺激因子I期临床耐受性试验[J].癌症,2006,25(4):495-500. 被引量:31
  • 2石远凯,何小慧,杨晟,王华庆,江泽飞,朱允中,克晓燕,张阳,刘云鹏,张伟京,王昭,石庆芝,谢晓冬,张贺龙,王杰军,罗德云,郑青山,孙瑞元.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J].中华医学杂志,2006,86(48):3414-3419. 被引量:43
  • 3Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 4Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 5Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 6Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 7Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 8Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 9Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 10Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.

共引文献369

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部